Advertisement

Current Diabetes Reports

, Volume 4, Issue 4, pp 304–309 | Cite as

Risks and side effects of islet transplantation

  • Edmond A. Ryan
  • Breay W. Paty
  • Peter A. Senior
  • A. M. James Shapiro
Article

Abstract

Islet transplantation can deliver stable glycemic control, relief from recurrent severe hypoglycemia, and insulin independence. Accessing the portal vein via the percutaneous hepatic approach carries the risk of bleeding, and the infusion of islets a risk of portal vein thrombosis. In the long term, common minor problems with immunosuppression are mouth ulcers, diarrhea, and acne. Longer-term risks include malignancy and serious infection, both rare to date in clinical islet transplantation. Sensitization to donor antigens may also occur. The long-term diabetes complications may stabilize, but of this aspect little is known to date. In the short term, there may be some elevation of serum cholesterol and blood pressure, in some patients there has been a decline in renal function, and in a few, acute retinal bleeds. For most, improvement in glucose control with resolution of glycemic lability and hypoglycemia has been a net benefit.

Keywords

Tacrolimus Hypoglycemia Sirolimus Portal Vein Thrombosis Islet Transplantation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Goss JA, Soltes G, Goodpastor SE, et al.: Pancreatic islet transplantation: the radiographic approach. Transplantation 2003, 76:199–203.PubMedCrossRefGoogle Scholar
  2. 2.
    Owen RJ, Ryan EA, O'Kelly K, et al.: Percutaneous transhepatic pancreatic islet cell transplantation in type 1 diabetes mellitus: radiologic aspects. Radiology 2003, 229:165–170.PubMedCrossRefGoogle Scholar
  3. 3.
    Hering BJ, Kandaswamy R, Harmon JV, et al.: Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant 2004, 4:390–401. Demonstrates that with careful selection of donors and recipients a single transplant may suffice to provide insulin independence.PubMedCrossRefGoogle Scholar
  4. 4.
    Ryan EA, Shandro T, Green K, et al.: Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes 2004, 53:955–962. Provides standardized measures of hypoglycemia and lability and the improvement of these after islet transplant.PubMedCrossRefGoogle Scholar
  5. 5.
    Kessler L, Passemard R, Oberholzer J, et al.: Reduction of blood glucose variability in type 1 diabetic patients treated by pancreatic islet transplantation. Diabetes Care 2002, 25:2256–2262.PubMedCrossRefGoogle Scholar
  6. 6.
    Shapiro AMJ, Lakey JRT, Ryan EA, et al.: Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000, 343:230–238. First use of a steroid-free protocol for islet transplantation, heralding new era in the field.PubMedCrossRefGoogle Scholar
  7. 7.
    Hirshberg B, Rother KI, Digon BJ III, et al.: Benefits and risks of solitary islet transplantation for type 1 diabetes using steroid-sparing immunosuppression. Diabetes Care 2003, 26:3288–3295. Experience, both good and bad, in a center starting an islet transplant program.PubMedCrossRefGoogle Scholar
  8. 8.
    Ryan EA, Lakey JRT, Rajotte RV, et al.: Clinical outcomes and insulin secretion after islet transplantation with the Edmonton Protocol. Diabetes 2001, 50:710–719.PubMedCrossRefGoogle Scholar
  9. 9.
    Markmann JF, Deng S, Huang X, et al.: Insulin independence following isolated islet transplantation and single islet infusions. Ann Surg 2003, 237:741–750. Confirms that insulin independence can be obtained once adequate islet mass is transplanted.PubMedCrossRefGoogle Scholar
  10. 10.
    Fiorina P, Folli F, Maffi P, et al.: Islet transplantation improves vascular diabetic complications in patients with diabetes who underwent kidney transplantation: a comparison between kidney-pancreas and kidney-alone transplantation. Transplantation 2003, 75:1296–1301.PubMedCrossRefGoogle Scholar
  11. 11.
    Robertson RP: Islet transplantation as a treatment for diabetes: a work in progress. N Engl J Med 2004, 350:694–705. Excellent review of the field of islet transplantation.PubMedCrossRefGoogle Scholar
  12. 12.
    Fiorina P, Folli F, Bertuzzi F, et al.: Long-term beneficial effect of islet transplantation on diabetic macro-/microangiopathy in type 1 diabetic kidney-transplanted patients. Diabetes Care 2003, 26:1129–1136. Demonstration of the benefit of long-term function of islets after transplantation in terms of vascular disease.PubMedCrossRefGoogle Scholar
  13. 13.
    Ryan EA, Lakey JRT, Paty BW, et al.: Successful islet transplantation. Continued insulin reserve provides long-term glycemic control. Diabetes 2002, 51:2148–2157.PubMedCrossRefGoogle Scholar
  14. 14.
    Moberg L, Johansson H, Lukinius A, et al.: Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet 2002, 360:2039–2045.PubMedCrossRefGoogle Scholar
  15. 15.
    Bertuzzi F, Grohovaz F, Maffi P, et al.: Successful transplantation of human islets in recipients bearing a kidney graft. Diabetologia 2002, 45:77–84.PubMedCrossRefGoogle Scholar
  16. 16.
    Gaber AO, Chamsuddin A, Fraga D, et al.: Insulin independence achieved using the transmesenteric approach to the portal vein for islet transplantation. Transplantation 2004, 77:309–311.CrossRefGoogle Scholar
  17. 17.
    Weimar B, Rauber K, Brendel MD, et al.: Percutaneous transhepatic catheterization of the portal vein: A combined CT-and fluoroscopy-guide technique. Cardiovasc Intervent Radiol 1999, 22:342–344.PubMedCrossRefGoogle Scholar
  18. 18.
    Walsh TJ, Eggleston JC, Cameron JL: Portal hypertension, hepatic infarction, and liver failure complication pancreatic islet autotransplantation. Surgery 1982, 91:485–487.PubMedGoogle Scholar
  19. 19.
    Shapiro AMJ, Lakey JRT, Rajotte RV, et al.: Portal vein thrombosis after transplantation of partially purified pancreatic islets in a combined human liver/islet allograft. Transplantation 1995, 59:1060–1063.PubMedGoogle Scholar
  20. 20.
    Rafael E, Ryan EA, Paty BW, et al.: Changes in liver enzymes after clinical islet transplantation. Transplantation 2003, 76:1280–1284.PubMedCrossRefGoogle Scholar
  21. 21.
    Casey JJ, Lakey JRT, Ryan EA, et al.: Portal venous pressure changes after sequential clinical islet transplantation. Transplantation 2002, 74:913–915.PubMedCrossRefGoogle Scholar
  22. 22.
    Markmann JF, Rosen M, Siegelman ES, et al.: Magnetic resonance defined periportal steatosis following intraportal islet transplantation: a functional footprint of islet graft survival? Diabetes 2003, 52:1591–1594.PubMedCrossRefGoogle Scholar
  23. 23.
    Bhargava R, Senior PA, Ackerman TE, et al.: Prevalence of hepatic steatosis after islet transplantation and its relationship to graft function. Diabetes 2004, 53:1311–1317.PubMedCrossRefGoogle Scholar
  24. 24.
    Clayton HA, Davies JE, Pollard CA, et al.: Pancreatectomy with islet autotransplantation for the treatment of severe chronic pancreatitis: the first 40 patients at the Leicester general hospital. Transplantation 2003, 76:92–98.PubMedCrossRefGoogle Scholar
  25. 25.
    Pyzdrowski KL, Kendall DM, Halter JB, et al.: Preserved insulin secretion and insulin independence in recipients of islet autografts. N Engl J Med 1992, 327:220–226.PubMedCrossRefGoogle Scholar
  26. 26.
    Robertson RP, Lanz KJ, Sutherland DE, Kendall DM: Prevention of diabetes for up to 13 years by autoislet transplantation after pancreatectomy for chronic pancreatitis. Diabetes 2001, 50:47–50.PubMedCrossRefGoogle Scholar
  27. 27.
    Digon BJ III, Rother KI, Hirshberg B, Harlan DM: Sirolimusinduced interstitial pneumonitis in an islet transplant recipient. Diabetes Care 2003, 26:3191.PubMedCrossRefGoogle Scholar
  28. 28.
    Johnson JA, Kotovych M, Ryan EA, Shapiro AM: Reduced fear of hypoglycemia in successful islet transplantation. Diabetes Care 2004, 27:624–625.PubMedCrossRefGoogle Scholar
  29. 29.
    Eckhard M, Martin I, Eich T, et al.: Incidence of cytomegalovirus infections after immunosuppression induction in clinical islet transplantation and impact on graft function. Transplant Proc 2002, 34:1922–1924.PubMedCrossRefGoogle Scholar
  30. 30.
    Tremblay F, Fernandes M, Habbab F, et al.: Malignancy after renal transplantation: incidence and role of type of immunosuppression. Ann Surg Oncol 2003, 98:785–788.Google Scholar
  31. 31.
    Lutz J, Heemann U: Tumours after kidney transplantation. Curr Opin Urol 2003, 13:105–109.PubMedCrossRefGoogle Scholar
  32. 32.
    Euvrard S, Kanitakis J, Claudy A: Skin cancers after organ transplantation. N Engl J Med 2003, 348:1681–1691.PubMedCrossRefGoogle Scholar
  33. 33.
    Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF, et al.: Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study. BMJ 1985, 290:811–815.PubMedCrossRefGoogle Scholar
  34. 34.
    Lauritzen T, Frost-Larsen K, Larsen H-W, Deckert T: Effect of 1 year of near-normal blood glucose levels on retinopathy in insulin-dependent diabetics. Lancet 1983, 1:200–204.PubMedCrossRefGoogle Scholar
  35. 35.
    Fuchsjägger-Mayrl G, Kautzky-Willer A, Kiss B, et al.: Ocular hyperperfusion following onset of intensified insulin therapy is inversely correlated with plasma endothelin-1 in type 1 diabetes. Diabetologia 2002, 45:883–889.CrossRefGoogle Scholar
  36. 36.
    Königsrainer A, Miller K, Steurer W, et al.: Does pancreas transplantation influence the course of diabetic retinopathy? Diabetologia 1991, 34(suppl 1):S86-S88.PubMedCrossRefGoogle Scholar
  37. 37.
    Chow VCC, Pai RP, Chapman JR, et al.: Diabetic retinopathy after combined kidney-pancreas transplantation. Clin Transplant 2003, 13:356–362.CrossRefGoogle Scholar
  38. 38.
    Koznarova R, Saudek F, Sosna T, et al.: Beneficial effects of pancreas and kidney transplantation on advanced diabetic retinopathy. Cell Transplant 2000, 9:903–908.PubMedGoogle Scholar
  39. 39.
    Ojo AO, Held PJ, Port FK, et al.: Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003, 349:931–940.PubMedCrossRefGoogle Scholar
  40. 40.
    Perlman A, Moore J, Kim E, et al.: Clinically significant proteinuria following the administration of sirolimus to renal transplant recipients. J Am Soc Nephrol 2003, 14:645A-646A.Google Scholar
  41. 41.
    Jim B, Doyle A, Bloom RD: Rapamycin is associated with worsening proteinuria in transplant patients with renal injury: a report of four cases. J Am Soc Nephrol 2003, 14:65A.CrossRefGoogle Scholar
  42. 42.
    Fioretto P, Steffes MW, Sutherland DE, et al.: Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998, 339:69–75.PubMedCrossRefGoogle Scholar
  43. 43.
    Groth CG, Backman L, Morales JM, et al.: Sirolimus (rapamycin)-based therapy in human renal transplantation. Transplantation 2002, 67:1036–1042.CrossRefGoogle Scholar
  44. 44.
    Trotter JF, Wachs ME, Trouillot TE, et al.: Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not with tacrolimus. Liver Transpl 2001, 7:401–408.PubMedCrossRefGoogle Scholar
  45. 45.
    Fiorina P, La Rocca E, Venturini M, et al.: Effects of kidneypancreas transplantation on atherosclerotic risk factors and endothelial function in patients with uremia and type 1 diabetes. Diabetes 2001, 50:496–501.PubMedCrossRefGoogle Scholar
  46. 46.
    Navarro X, Sutherland DE, Kennedy WR: Long-term effects of pancreatic transplantation on diabetic neuropathy. Ann Neurol 1997, 42:727–736.PubMedCrossRefGoogle Scholar
  47. 47.
    Brendel MD, Hering B, Schulz AO, Bretzel RG: International Islet Transplant Registry Report. 1-20. Giessen, Germany: Justus-Liebig University of Giessen; 1999.Google Scholar
  48. 48.
    Luzi L, Perseghin G, Brendel MD, et al.: Metabolic effects of restoring partial beta-cell function after islet allotransplantation in type 1 diabetic patients. Diabetes 2001, 50:277–282.PubMedCrossRefGoogle Scholar
  49. 49.
    Jaeger C, Brendel MD, Hering BJ, et al.: Progressive islet graft failure occurs significantly earlier in autoantibody-positive than in autoantibody-negative IDDM recipients of intrahepatic islet allografts. Diabetes 1997, 46:1907–1910.PubMedCrossRefGoogle Scholar
  50. 50.
    Bosi E, Braghi S, Maffi P, et al.: Autoantibody response to islet transplantation in type 1 diabetes. Diabetes 2001, 50:2464–2471.PubMedCrossRefGoogle Scholar
  51. 51.
    Paty BW, Ryan EA, Shapiro AMJ, et al.: Intrahepatic islet transplantation in type 1 diabetic patients does not restore hypoglycemic hormonal counterregulation or symptom recognition after insulin independence. Diabetes 2002, 51:3428–3434.PubMedCrossRefGoogle Scholar
  52. 52.
    Kendall DM, Teuscher AU, Robertson RP: Defective glucagon secretion during sustained hypoglycemia following successful islet allo-and autotransplantation in humans. Diabetes 1997, 46:23–27.PubMedCrossRefGoogle Scholar
  53. 53.
    Paty BW, Lanz K, Kendall DM, et al.: Restored hypoglycemic counterregulation is stable in successful pancreas transplant recipients for up to 19 years after transplantation. Transplantation 2001, 72:1103–1107.PubMedCrossRefGoogle Scholar
  54. 54.
    Gupta V, Wahoff DC, Rooney DP, et al.: The defective glucagon response from transplanted intrahepatic pancreatic islets during hypoglycemia is transplantation site-determined. Diabetes 1997, 46:28–33.PubMedCrossRefGoogle Scholar
  55. 55.
    Kiberd B: Estimating the benefits of solitary pancreas and islet cell transplantation in type 1 diabetes mellitus. Can J Diabetes Care 2001, 25(suppl 2):96–102.Google Scholar

Copyright information

© Current Science Inc 2004

Authors and Affiliations

  • Edmond A. Ryan
    • 1
  • Breay W. Paty
  • Peter A. Senior
  • A. M. James Shapiro
  1. 1.Clinical Islet Transplant ProgramEdmontonCanada

Personalised recommendations